Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients

被引:4
|
作者
Naicker, Derisha [1 ]
Reed, Peter W. [2 ]
Ronaldson, Jane [1 ]
Kara, Tonya [1 ]
Wong, William [1 ]
Prestidge, Chanel [1 ]
机构
[1] Starship Childrens Hosp, Dept Pediat Nephrol, Pk Rd,Private Bag 92024, Auckland 1142, New Zealand
[2] Starship Childrens Hosp, Childrens Res Ctr, Auckland, New Zealand
关键词
Calcineurin inhibitor; Generic Immunosuppression; Renal; Tacrolimus; Transplantation; IMMUNOSUPPRESSION; PROGRAF; DRUGS;
D O I
10.1007/s00467-017-3707-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Bioequivalence between Tacrolimus Prograf (R) and generic tacrolimus formulations has been demonstrated in adult populations,however clinical experience and safety data regarding generic tacrolimus in pediatric transplant recipients is limited. This study aimed to evaluate conversion from Tacrolimus Prograf (R) to Sandoz (R) in pediatric renal transplant recipients nationwide. The primary outcome was a change in mean trough tacrolimus concentration. Additionally, changes in tacrolimus intra-patient coefficient of variation (CoV), allograft function, requirement for dose adjustments, and episodes of biopsy-proven rejection were evaluated. Methods Retrospective cohort study in 37 pediatric renal transplant recipients who switched to Tacrolimus Sandoz (R). Each patient had three pre-conversion tacrolimus trough and creatinine concentrations within the 4 months prior and three post-conversion concentrations on day 3, 10, and the next subsequent level. Mean pre-and post-conversion tacrolimus trough concentrations and glomerular filtration rate (eGFR) were calculated. Tacrolimus concentration, CoV, and creatinine differences were compared by paired t test. Results Thirty-seven patients (41% females, age 3-18 years) were included. Average intra-patient difference in trough tacrolimus concentration was 0.05 mu g/l (95% CI -0.37 to 0.47). Average intra-patient difference in eGFR was -1.20 ml/min/1.73(2) (95% CI -3.53 to 1.13). Three patients had acute rejection during 12 months post-conversion compared to none during 12 months pre-conversion. Conclusions Pediatric renal transplant recipients can be converted from Tacrolimus Prograf (R) to Sandoz (R) with negligible change in trough concentration, dose adjustments, or immediate allograft function. Of concern was the number of acute rejection episodes, however non-adherence contributed to at least one episode and this difference was determined clinically and statistically not significant.
引用
收藏
页码:2125 / 2131
页数:7
相关论文
共 50 条
  • [1] Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients
    Derisha Naicker
    Peter W. Reed
    Jane Ronaldson
    Tonya Kara
    William Wong
    Chanel Prestidge
    Pediatric Nephrology, 2017, 32 : 2125 - 2131
  • [2] Nationwide conversion to generic tacrolimus in paediatric kidney transplant recipients
    Naicker, Derisha
    Kara, Tonya
    Wong, William
    Prestidge, Chanel
    TRANSPLANTATION, 2016, 100 (07) : S315 - S315
  • [3] Systematic conversion to generic tacrolimus in stable kidney transplant recipients
    Rosenborg, Staffan
    Nordstrom, Annica
    Almquist, Tora
    Wennberg, Lars
    Barany, Peter
    CLINICAL KIDNEY JOURNAL, 2014, 7 (02) : 151 - 155
  • [4] Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients
    Mariano Ferraresso
    Luciana Ghio
    Alberto Edefonti
    Rosanna Garavaglia
    Luisa Berardinelli
    Pediatric Nephrology, 2002, 17 : 664 - 667
  • [5] Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients
    Ferraresso, M
    Ghio, L
    Edefonti, A
    Garavaglia, R
    Berardinelli, L
    PEDIATRIC NEPHROLOGY, 2002, 17 (08) : 664 - 667
  • [6] Generic Tacrolimus Is a Safe Alternative to Brand Prograf in Pediatric Kidney Transplant Recipients
    Marfo, K.
    Hayde, N.
    Yeboah, P.
    Del Rio, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 442 - 442
  • [7] Conversion of Prograf® to Generic Tacrolimus in Stable Renal Transplant Recipients
    Crowther, B. R.
    Dobie, H.
    Brady, R.
    Hall, R.
    Maxwell, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 203 - 203
  • [8] Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients
    Efe, Orhan
    Al Jurdi, Ayman
    Eiting, Morgan Mabey
    Marks, Christine Rogers
    Cote, Mariesa Ann
    Wojciechowski, David
    Safa, Kassem
    Gilligan, Hannah
    Azzi, Jamil
    Goyal, Nitender
    Raynaud, Marc
    Loupy, Alexandre
    Weins, Astrid
    Riella, Leonardo V.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [9] The Effect of Generic Substitution of Tacrolimus in Liver and Kidney Transplant Recipients
    Venkataramanan, R.
    Raghu, V.
    Momper, J.
    Schonder, K.
    Shapiro, R.
    Humar, A.
    TRANSPLANTATION, 2012, 94 (10) : 748 - 748
  • [10] Generic Switch of Tacrolimus in Prevalent Kidney Transplant Recipients.
    Jogia, P.
    Oskiera, D.
    Booth, S.
    McKane, W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 226 - 226